AU2006315686A1 - Modulation of angiogenesis by A-beta peptide fragments - Google Patents

Modulation of angiogenesis by A-beta peptide fragments Download PDF

Info

Publication number
AU2006315686A1
AU2006315686A1 AU2006315686A AU2006315686A AU2006315686A1 AU 2006315686 A1 AU2006315686 A1 AU 2006315686A1 AU 2006315686 A AU2006315686 A AU 2006315686A AU 2006315686 A AU2006315686 A AU 2006315686A AU 2006315686 A1 AU2006315686 A1 AU 2006315686A1
Authority
AU
Australia
Prior art keywords
fragment
peptide
angiogenic
peptide fragment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006315686A
Other languages
English (en)
Inventor
Michael J. Mullan
Daniel Paris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roskamp Research LLC
Original Assignee
Roskamp Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roskamp Research LLC filed Critical Roskamp Research LLC
Publication of AU2006315686A1 publication Critical patent/AU2006315686A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006315686A 2005-11-10 2006-11-13 Modulation of angiogenesis by A-beta peptide fragments Abandoned AU2006315686A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73547205P 2005-11-10 2005-11-10
US60/735,472 2005-11-10
PCT/US2006/043921 WO2007059000A2 (en) 2005-11-10 2006-11-13 Modulation of angiogenesis by a-beta peptide fragments

Publications (1)

Publication Number Publication Date
AU2006315686A1 true AU2006315686A1 (en) 2007-05-24

Family

ID=38049186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006315686A Abandoned AU2006315686A1 (en) 2005-11-10 2006-11-13 Modulation of angiogenesis by A-beta peptide fragments

Country Status (8)

Country Link
US (1) US8067372B2 (https=)
EP (1) EP1951750A4 (https=)
JP (1) JP2009516654A (https=)
KR (1) KR20080095836A (https=)
CN (1) CN101558080A (https=)
AU (1) AU2006315686A1 (https=)
CA (1) CA2619455A1 (https=)
WO (1) WO2007059000A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20080292625A1 (en) * 2007-04-18 2008-11-27 Sally Schroeter Prevention and treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009143489A2 (en) * 2008-05-22 2009-11-26 Archer Pharmaceuticals, Inc. Modulation of angiogenesis by a-beta peptide fragments
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US10882890B2 (en) * 2014-07-25 2021-01-05 Academia Sinica Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004494A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105009A (en) * 1959-10-30 1963-09-24 Us Rubber Co Anti-mitotic chemotherapeutic compounds
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
DE667959T1 (de) 1992-10-26 2000-04-20 Dale B Schenk VERFAHREN UND ZUSAMMENSETZUNGEN FÜR DEN NACHWEIS VON LÖSLICHEM-g(b)-AMYLOIDPEPTID.
WO1994012627A1 (en) 1992-11-25 1994-06-09 Cephalon, Inc. Transgenic animal model for alzheimer's disease
EP0815134B1 (en) * 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
NZ540564A (en) 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
CA2467922A1 (en) * 2001-08-10 2003-02-20 Roskamp Research, Llc Modulation of angiogenesis by a-beta peptides
GB0207362D0 (en) * 2002-03-28 2002-05-08 Univ Liverpool Chemotherapy
US8067372B2 (en) 2005-11-10 2011-11-29 Alzheimer's Institute Of America, Inc. Modulation of angiogenesis by A-beta peptide fragments

Also Published As

Publication number Publication date
WO2007059000A3 (en) 2009-05-14
US8067372B2 (en) 2011-11-29
CA2619455A1 (en) 2007-05-24
US20080031954A1 (en) 2008-02-07
EP1951750A2 (en) 2008-08-06
EP1951750A4 (en) 2009-12-09
KR20080095836A (ko) 2008-10-29
WO2007059000A2 (en) 2007-05-24
JP2009516654A (ja) 2009-04-23
CN101558080A (zh) 2009-10-14

Similar Documents

Publication Publication Date Title
AU2006315686A1 (en) Modulation of angiogenesis by A-beta peptide fragments
US20060147945A1 (en) Novel secreted proteins and their uses
CA2367750C (en) Tribonectins
WO2002014358A2 (en) Novel secreted proteins and their uses
US20040038242A1 (en) Novel secreted proteins and their uses
US6960562B2 (en) Tribonectin polypeptides and uses thereof
US8637470B2 (en) Small humanin-like peptides
KR20120024741A (ko) 신경변성 질환과 알츠하이머병을 치료하고 정상 기억을 향상시키기 위한 방법과 조성물
CA2443338A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
US7589168B2 (en) Inhibition of angiogenesis by A-β peptides
WO2009143489A2 (en) Modulation of angiogenesis by a-beta peptide fragments
US20030208051A1 (en) Human hepatocyte growth factor activator inhibitor homologue
JP2008013436A (ja) 血管形成促進剤
US20050048483A1 (en) Novel secreted proteins and their uses
US20100130416A1 (en) Modulation of angiogenesis by a-beta peptide fragments
WO2002048361A2 (en) Novel secreted proteins and their uses
WO2002016578A2 (en) Secreted proteins and methods of using same
US20030212258A1 (en) Novel secreted proteins and methods of using same
US20040215007A1 (en) Novel secreted proteins and their uses
US20060142558A1 (en) Novel proteins and their uses
EP1500663A1 (en) Secreted proteins and their uses
WO2004044126A2 (en) Novel proteins and their uses
JPWO2002038763A1 (ja) Ｐｃａ２５０１遺伝子
EP1529843A2 (en) Novel secreted proteins and their uses
HK1095743A1 (en) Ccn1 compositions and methods

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period